New Drug Application submitted to FDA for accelerated approval of melflufen injection in combination with dexamethasone for treatment of triple-class refractory multiple myeloma

Application for this first-in-class aminopeptidase-targeting peptide-drug conjugate is for use in adult patients whose disease is refractory to ≥1 proteasome inhibitor, 1 immunomodulatory agent and 1 anti-CD38 monoclonal antibody, and is based on phase II HORIZON, study.


Biospace Inc.